Products for Research Use Only
RegisterLogin

Mibefradil

CAT: 0804-HY-15553-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-15553-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Mibefradil (Ro 40-5967) is a calcium channel blocker with moderate selectivity for T-type Ca2+ channels displaying IC50s of 2.7 μM and 18.6 μM for T-type and L-type currents, respectively[1].
CAS Number
116644-53-2
Product Name Alternative
Ro 40-5967
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Calcium Channel
Type
Reference compound
Related Pathways
Membrane Transporter/Ion Channel; Neuronal Signaling
Applications
Neuroscience-Neuromodulation
Field of Research
Cardiovascular Disease; Cancer
Assay Protocol
https://www.medchemexpress.com/mibefradil.html
Purity
99.29
Solubility
10 mM in DMSO
Smiles
O=C(O[C@@]1(CCN(CCCC2=NC3=CC=CC=C3N2)C)[C@@H](C(C)C)C4=C(C=C(F)C=C4)CC1)COC
Molecular Formula
C29H38FN3O3
Molecular Weight
495.63
Precautions
H302, H315, H319, H335
References & Citations
[1]Mehrke G, et al. The Ca (++) -channel blocker Ro 40-5967 blocks differently T-type and L-type Ca++ channels. J Pharmacol Exp Ther. 1994 Dec;271 (3) :1483-8.|[2]Brain KL, et al. The sources and sequestration of Ca (2+) contributing to neuroeffector Ca (2+) transients in the mouse vas deferens. J Physiol. 2003 Dec 1;553 (Pt 2) :627-35.|[3]Yu YF, et al. Protection of the cochlear hair cells in adult C57BL/6J mice by T-type calcium channel blockers. Exp Ther Med. 2016 Mar;11 (3) :1039-1044.|[4]Shiue SJ, et al. Chronic intrathecal infusion of T-type calcium channel blockers attenuates CaV3.2 upregulation in nerve-ligated rats. Acta Anaesthesiol Taiwan. 2016 Oct 17. pii: S1875-4597 (16) 30071-6.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, sealed storage, away from moisture and light)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
L-type calcium channel; T-type calcium channel
Citation 01
Biochem Biophys Res Commun. 2020 Feb 19;522 (4) :862-868.|Br J Pharmacol. 2021 Jan;178 (2) :346-362.|Eur J Pharmacol. 2021 Feb 5;892:173782.|Front Pharmacol. 2022 Feb 23:13:816133.|J Cell Physiol. 2021 Sep;236 (9) :6548-6558.|Mediators Inflamm. 2020 Nov 10;2020:3691701.|Theriogenology. 2021 Jan 1;159:140-146.|ACS Nano. 2024 Nov 12;18 (45) :31451-31465.|Biochem Biophys Res Commun. 2025 Sep 19:785:152676.|Front Pharmacol. 2022 Feb 23;13:816133.|PLoS Biol. 2024 Mar 25;22 (3) :e3002565.|Res Sq. 2024 Jun 11.|Small. 2024 Aug 10:e2403381.

Alternative Products

CatalogName
E7529-1mgMibefradil
TRC-M341803-25MGMibefradil Dihydrochloride
A12478-10Mibefradil 10mg
sc-487927Mibefradil hihydrochloride
FM65086-01Mibefradil hydrochloride

Popular Products